The steroid derivative 6-aminocholestanol inhibits the DEAD-box helicase eIF4A (LieIF4A) from the Trypanosomatid parasite Leishmania by perturbing the RNA and ATP binding sites

Yosser Zina Abdelkrim, Emna Harigua‐Souiai, Mourad Barhoumi, Josette Banroques, Arnaud Blondel, Ikram Guizani, N. Kyle TannerMolecular 2018 · DOI

TL;DR

This study investigates the mechanism by which 6-aminocholestanol, a steroid derivative, inhibits the Leishmania DEAD-box helicase LieIF4A. The findings reveal that the compound competitively disrupts both ATP and RNA binding, leading to inhibition of helicase activity, and suggest potential for developing selective anti-parasitic drugs targeting these essential helicases.

What Problem Does This Paper Address?

Leishmaniasis, a group of neglected tropical diseases, poses a significant global health burden, particularly in developing countries. Current treatments are often expensive, toxic, and face the challenge of parasite drug resistance. The development of new, selective, and affordable drugs is therefore crucial. DEAD-box helicases are essential proteins involved in various RNA-related processes, including translation, making them attractive targets for drug development. This paper focuses on LieIF4A, a Leishmania DEAD-box helicase, and explores the potential of 6-aminocholestanol, a known antifungal agent, as an inhibitor. The research aims to understand how 6-aminocholestanol interacts with LieIF4A and whether this interaction can be exploited for therapeutic purposes against Leishmania.

Methods

The study employed a multi-faceted approach combining biochemical assays, molecular modeling, and computational simulations:

  • ATPase Assays: Kinetic analyses (Michaelis-Menten and Lineweaver-Burke plots) were used to determine the inhibition constants ($K_i$) and understand the competitive or non-competitive nature of 6-aminocholestanol's inhibition of LieIF4A's ATP hydrolysis activity.
  • RNA Helicase Assays: Standard helicase assays were performed using radiolabeled RNA duplexes to measure the unwinding activity of LieIF4A and its inhibition by 6-aminocholestanol.
  • Molecular Modeling and Dynamics: Molecular dynamics (MD) simulations were used to generate "open" and "closed" conformations of LieIF4A.
  • Cavity Analysis: An in-house software (mkgridX) was used to search for potential binding cavities and pockets on the protein surface in both open and closed conformations.
  • Molecular Docking: AutoDock 4.2 was employed to dock 6-aminocholestanol into the identified pockets of LieIF4A, as well as control proteins (eIF4AIMus, Gp32, BSA), to predict binding modes and estimate binding energies.
  • Competition Assays: Experiments using isolated RecA-like domains of LieIF4A (domain 1 and domain 2), as well as other proteins like Gp32 and BSA, were conducted to assess the specificity of 6-aminocholestanol binding and its ability to sequester the compound.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Dual Inhibition: 6-aminocholestanol doesn't just target one aspect of LieIF4A's function; it competitively inhibits both ATP and RNA binding, leading to a comprehensive shutdown of its helicase activity.
  • Multiple Binding Sites: The compound isn't a one-trick pony. Computational analysis revealed several potential binding pockets on LieIF4A, suggesting a degree of flexibility in how it interacts with the protein.
  • Domain 1 Preference: While multiple sites exist, RecA-like domain 1 appears to be a preferred binding site for 6-aminocholestanol, particularly in the "open" conformation of the protein. This aligns with previous modeling predictions.
  • Differential Effects: Crucially, 6-aminocholestanol affects the Leishmania LieIF4A and the mammalian eIF4AI differently. This difference in binding sites and affinities is a critical insight for developing selective drugs.
  • Potential for Specificity: The observation that 6-aminocholestanol binds to certain sites with higher affinity suggests that its chemical structure can be modified to enhance specificity for parasitic DEAD-box helicases, minimizing off-target effects on human proteins.

Key Results

  • 6-aminocholestanol competitively inhibits LieIF4A's ATPase activity with a $K_i$ of approximately 100 µM, indicating a higher affinity for the compound than for ATP.
  • The compound also reduces LieIF4A's RNA binding affinity, increasing the $K_m$ for RNA by 3.6-fold.
  • 6-aminocholestanol inhibits LieIF4A's helicase activity by 3.3- to 5.6-fold.
  • Molecular docking identified five significant binding pockets on LieIF4A, with pocket P11 in domain 1 being a primary site.
  • Competition assays showed that isolated RecA-like domain 1 was more effective than domain 2 in sequestering 6-aminocholestanol, supporting its role as a primary binding site.
  • The compound also inhibited the mammalian eIF4AIMus, but with different binding sites and affinities, highlighting the potential for selective targeting.

Limitations and Future Work

  • DMSO Effects: The study acknowledges that DMSO, used to solubilize the compound, may have affected protein flexibility and enzymatic activity, potentially influencing the observed kinetic parameters. Future work could explore the effects of alternative solvents or the compound in its native state.
  • Modeled Structures: Docking scores on modeled structures may not perfectly represent actual binding affinities. The authors note that this is a common limitation and that their molecular dynamics simulations did not fully account for DMSO's effects.
  • Crystal Structure: The authors are currently working on obtaining a crystal structure of LieIF4A bound to the compound. This would provide definitive structural information and greatly facilitate the design of more specific derivatives.
  • Derivative Screening: The study suggests that screening a wide variety of hydroxycholestanol derivatives could lead to the identification of compounds with enhanced specificity for Leishmania eIF4A.
  • Further Characterization: While the study demonstrates inhibition, further work is needed to fully elucidate the precise roles of all identified binding pockets and their contribution to the overall inhibitory effect.

Summary updated

BibTeX
@inproceedings{abdelkrim2018steroid,
  author = {Yosser Zina Abdelkrim and Emna Harigua‐Souiai and Mourad Barhoumi and Josette Banroques and Arnaud Blondel and Ikram Guizani and N. Kyle Tanner},
  title = {{The steroid derivative 6-aminocholestanol inhibits the DEAD-box helicase eIF4A (LieIF4A) from the Trypanosomatid parasite Leishmania by perturbing the RNA and ATP binding sites}},
  booktitle = {Molecular},
  year = {2018},
  doi = {10.1016/j.molbiopara.2018.10.001},
}
Figure